- Home
- CASI vs GRF Comparison
CASI vs GRF Comparison
Compare CASI & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- GRF
- Stock Information
- Founded
- CASI 1991
- GRF 1989
- Country
- CASI China
- GRF United States
- Employees
- CASI N/A
- GRF N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- GRF Finance/Investors Services
- Sector
- CASI Health Care
- GRF Finance
- Exchange
- CASI Nasdaq
- GRF Nasdaq
- Market Cap
- CASI 35.8M
- GRF 42.6M
- IPO Year
- CASI 1996
- GRF N/A
- Fundamental
- Price
- CASI $2.01
- GRF $10.52
- Analyst Decision
- CASI Strong Buy
- GRF
- Analyst Count
- CASI 1
- GRF 0
- Target Price
- CASI $4.00
- GRF N/A
- AVG Volume (30 Days)
- CASI 76.1K
- GRF 3.0K
- Earning Date
- CASI 11-13-2025
- GRF 01-01-0001
- Dividend Yield
- CASI N/A
- GRF 3.70%
- EPS Growth
- CASI N/A
- GRF N/A
- EPS
- CASI N/A
- GRF 1.16
- Revenue
- CASI $31,564,000.00
- GRF N/A
- Revenue This Year
- CASI N/A
- GRF N/A
- Revenue Next Year
- CASI N/A
- GRF N/A
- P/E Ratio
- CASI N/A
- GRF $8.15
- Revenue Growth
- CASI 36.64
- GRF N/A
- 52 Week Low
- CASI $1.09
- GRF $7.93
- 52 Week High
- CASI $7.50
- GRF $10.19
- Technical
- Relative Strength Index (RSI)
- CASI 50.04
- GRF 52.48
- Support Level
- CASI N/A
- GRF $10.50
- Resistance Level
- CASI $2.49
- GRF $10.61
- Average True Range (ATR)
- CASI 0.17
- GRF 0.10
- MACD
- CASI -0.14
- GRF -0.02
- Stochastic Oscillator
- CASI 80.40
- GRF 22.45
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.